Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium

Therapeutic Drug Monitoring

Volumn 30, Issue 4, 2008, Pages 544-547

  Franco, Valentina ^a   Mazzucchelli, Iolanda ^a   Gatti, Giuliana ^a   Specchio, Luigi Maria ^b   Neve, Angela La ^c   Papantonio, Annamaria ^b   Özkaynakçi, Aydan Ergün ^d   Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d Medical School   (Turkey)

Author keywords

Epilepsy; Lamotrigine; Pharmacokinetics; Pregnancy; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; LAMOTRIGINE; PHENOBARBITAL; VIGABATRIN; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; DELIVERY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; EPILEPSY; FEMALE; FIRST TRIMESTER PREGNANCY; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; LONG TERM CARE; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; STEADY STATE; TONIC CLONIC SEIZURE; CALIBRATION; DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM;

ADULT; ANTICONVULSANTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FEMALE; HUMANS; POSTPARTUM PERIOD; PREGNANCY; TRIAZINES; YOUNG ADULT;

EID: 58149106223     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318178e2a9     Document Type: Article

References (19)

1. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology. 1992;42(Suppl 5):12-16.
2. Yerby MS, Friel PN, McCormick K, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res. 1990;5:223-228.
3. Koerner M, Yerby M, Friel P, et al. Valproic acid disposition and protein binding in pregnancy. Ther Drug Monit. 1989;11:228-230.
4. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet. 2007;46:209-219.
5. Tran TA, Leppijk IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology. 2002;59:251-255.
6. De Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology. 2004;63: 571-573.
7. Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology. 2004;62:292-295.
8. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 2005; 65:185-188.
9. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy. Clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70:2130-2136.
10. Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia. 2006;47:504-509.
11. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology. 2006;67:1497-1499.
12. Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48:1111-1116.
13. Bartoli A, Marchiselli R, Gatti G. A rapid and specific assay for the determination of lamotrigine in human plasma by normal phase-HPLC. Ther Drug Monit. 1997;19:100-107.
14. Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol. 1997; 12(Suppl 1):S10-S15.
15. Tomson T, Luef G, Sabers A, et al. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology. 2006;67:1297-1299.
16. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2:347-356.
17. Yuen AWC, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992;33:511-513.
18. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther. 1996:60:145-156.
19. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38:191-204.